
The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.

The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.

There is progress being made regarding research on immunotherapies and the mutation, which adversely affects a higher number of patients in this population.

Conducting clinical trials to investigate claims regarding supplements' safety and efficacy can support greater patient wellness.

Immune cells in lung cancer are connected to allergic conditions found in eczema and asthma.

Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.

Bivigam was initially approved by the FDA in May 2019 for the treatment of primary humoral immunodeficiency, including a group of genetic disorders.

Both individual and structural barriers were the most common hindrances to PrEP roll-out, and the investigators emphasize that efforts to remove the obstacles as well as further research can help improve PrEP implementation.

Fractional COVID-19 dosing resulted in fewer adverse effects and costs while producing similar immune responses compared to a full dose vaccine.

In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Axitinib, cabozantinib, and lenvatinib are first-line treatment options.

The products include Children’s Pain + Fever Gummy Bite, VapoPads Sinu, Clarifying Exfoliant 2% Salicylic Acid, and Menstrual Cramp Relief Cream.

Prefilled diluent and vaccine syringes may be easily mixed up

The study authors note that low skin cancer screening (SCS) participation, the participants’ better health than nonparticipants, and examination biases may be contributing factors to the insignificant results.

An FDA approval of 3,4-Methylenedioxy-methamphetamine (MDMA)–assisted therapy would require the Drug Enforcement Administration to reschedule MDMA in acknowledgement of its medical use, making it available for prescription medical use.

Troy Bremer, PhD, chief scientific officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.

Biologics for plaque psoriasis has been associated with an atopic dermatitis phenotype, paradoxical eczema, but the risk factors are not well known.

These data support the combination of daratumumab plus VRd followed by daratumumab and lenalidomide maintenance as a new standard of care for transplant-eligible patients.

Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML.

In a recent study, people who lived in disadvantaged or rural areas were just as likely to receive the second-generation medications as people in urban areas.

However, a survival benefit was observed with using a signaling inhibitor in general for patients with angioimmunoblastic T-cell lymphoma.

The authors note that CAR-T cell therapy could change the treatment standard for patients with DLBCL, who previously had few options if standard chemotherapy treatment was ineffective.

Encourage patients to locate and safely store their immunization records

The cases focus on acne, atopic dermatitis and steroids, warts and wart remover, and athlete’s foot.

Investigators found that individuals who self-identified as Black were less frequently imaged for cognitive impairment with MRI and at an older age compared with White and Hispanic patients.

An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.

The model may help clinicians identify patients who would benefit from disease-specific therapies or enrollment into clinical trials.

The study results demonstrated that 92% of patients treated with benralizumab were able to safely reduce inhaled steroid dose, and more than 60% could stop use entirely.

The results found that 93% of individuals in the high-risk group presented persistently positive antiphospholipid antibodies, compared with 47% of individuals in the lower-risk group.

Encouraging patients to take a proactive approach to their heart health can have great benefits

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.